Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Nova Eye Medical ( (AU:EYE) ) is now available.
Nova Eye Medical Limited reported a 32% increase in global sales, excluding China, for the quarter ending September 2025, with revenue reaching US$4.9 million. The company received approval from China’s National Medical Products Administration for its iTrack™ Advance product, which is expected to enhance its market presence in China. Despite slower-than-expected commercial expansion in the USA and Canada, the company reaffirmed its FY26 sales revenue guidance and is targeting improved cash flow and EBITDA breakeven by the second half of FY26.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company focused on developing advanced ophthalmic treatment technologies and devices.
Average Trading Volume: 301,365
Technical Sentiment Signal: Hold
Current Market Cap: A$44.86M
See more insights into EYE stock on TipRanks’ Stock Analysis page.